Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia.

Abraham Aseffa; Ahmed Bedru; Lawrence Yamuah; Demis Arga; Alemayehu Worku; Daniel Chandramohan ORCID logo; Christopher B Nelson; Howard D Engers; (2007) Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia. Vaccine, 25 Sup (SUPPL.). A79-A82. ISSN 0264-410X DOI: 10.1016/j.vaccine.2007.04.046
Copy

A phase II open and parallel reactogenicity, immunogenicity and safety trivalent meningitis vaccine (Mencevax) trial was conducted on 413 volunteer 2-29-year-old rural residents in Ethiopia in November/December 2005. Adverse events (AE) were monitored at 1h, 1, 2, 3, 7 and 28 days after vaccination. No serious AE occurred except for burn injury (one) and severe malaria (one) after day 28. Irritability (45/411), loss of appetite (27/411), pain at injection site (26/412), dizziness (18/409), crying (14/411), insomnia, headache and diarrhoea (13/411) were the most frequent AEs. Overall, the vaccine is safe in the age groups studied.
Item Type Article
Keywords Adolescent, Adult, Aged, Child, Child, Preschool, Dizziness, etiology, Ethiopia, Follow-Up Studies, Humans, Meningitis, Meningococcal, immunology, prevention & control, Meningococcal Vaccines, administration & dosage, adverse effects, immunology, Middle Aged, Neisseria meningitidis, Serogroup W-135, immunology, Pain, etiology, Sleep Initiation and Maintenance Disorders, etiology, Time Factors, Treatment Outcome
ISI 249521900016

Explore Further

Full text not available from this repository.

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads